Jinghui Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jinghui Li has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
Xin Geng
The Second Department of Neurosurgery The First Affiliated Hospital of Kunming Medical University Kunming 650032 Yunnan China kmmc.cn
6 shared publicationsRenli Qi
Second Department of Neurosurgery, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, China
5 shared publicationsWei Wang
The Second Department of Neurosurgery, First Affiliated Hospital of Kunming Medical University, Kunming, China
4 shared publicationsYanghong Zou
The Second Department of Neurosurgery The First Affiliated Hospital of Kunming Medical University Kunming 650032 Yunnan China kmmc.cn
4 shared publications- Hualin Yu
Second Department of Neurosurgery, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, China
3 shared publications - Renli Qi
The Second Department of Neurosurgery, First Affiliated Hospital of Kunming Medical University, Kunming, China
3 shared publications
Latest Publications
- Open Access
- 24 April 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (17) , e48332
Analysis of core target genes of vagus nerve stimulation in epilepsy, ischemic stroke, and depression: Separate insights from network pharmacology, bioinformatics, and Mendelian randomization
Epilepsy, ischemic stroke, and depression, as common neurological diseases, pose a serious threat to human health. Although vagus nerve stimulation (VNS) has been applied in the treatment of these diseases, its exact mechanism of action remains unclear. This study aims to deeply analyze the relationships between the core target genes of VNS and epilepsy, ischemic stroke, and depression by integrating network pharmacology, bioinformatics, and Mendelian randomization. The results showed that, compared with the control group, 159 differentially expressed genes were identified in the VNS-treated group. These genes were involved in biological processes such as “protein-RNA complex organization” and are enriched in metabolism-related pathways such as the “AMPK signaling pathway.” There were 73, 54, and 108 overlapping genes between VNS-related genes and genes related to epilepsy, ischemic stroke, and depression, respectively. Through network analysis and Mendelian randomization analysis, several core genes that may play a protective role in the corresponding diseases were identified, such as CPT1A , SUCLG1 , IMMT , IVD , and PSMA2 . This study has revealed the potential molecular mechanisms possibly involved in VNS treatment of these neurological diseases. The findings offer crucial clues for further in-depth study of VNS treatment mechanisms, and may boost the development of more precise and effective treatment strategies.
- 24 April 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (17) , e48332
Open AccessAnalysis of core target genes of vagus nerve stimulation in epilepsy, ischemic stroke, and depression: Separate insights from network pharmacology, bioinformatics, and Mendelian randomization
Epilepsy, ischemic stroke, and depression, as common neurological diseases, pose a serious threat to human health. Although vagus nerve stimulation (VNS) has been applied in the treatment of these diseases, its exact mechanism of action remains unclear. This study aims to deeply analyze the relationships between the core target genes of VNS and epilepsy, ischemic stroke, and depression by integrating network pharmacology, bioinformatics, and Mendelian randomization. The results showed that, compared with the control group, 159 differentially expressed genes were identified in the VNS-treated group. These genes were involved in biological processes such as “protein-RNA complex organization” and are enriched in metabolism-related pathways such as the “AMPK signaling pathway.” There were 73, 54, and 108 overlapping genes between VNS-related genes and genes related to epilepsy, ischemic stroke, and depression, respectively. Through network analysis and Mendelian randomization analysis, several core genes that may play a protective role in the corresponding diseases were identified, such as CPT1A , SUCLG1 , IMMT , IVD , and PSMA2 . This study has revealed the potential molecular mechanisms possibly involved in VNS treatment of these neurological diseases. The findings offer crucial clues for further in-depth study of VNS treatment mechanisms, and may boost the development of more precise and effective treatment strategies.
- Open Access
- 25 February 2026
- Published by Elsevier in Brain Research Bulletin
- Vol. 237, 111789
Vagus nerve stimulation enhances memory and long-term potentiation via the hippocampal NE/β-AR signaling pathway in pilocarpine rats
- 25 February 2026
- Published by Elsevier in Brain Research Bulletin
- Vol. 237, 111789
Open AccessVagus nerve stimulation enhances memory and long-term potentiation via the hippocampal NE/β-AR signaling pathway in pilocarpine rats
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 627
Identification of Mitochondrial Dysfunction-Related Candidate Biomarkers and Analysis of the Immune Cell Infiltration in Epilepsy
Epilepsy is a severe neurological disorder with complex pathogenesis. Mitochondrial dysfunction (MitD) is increasingly recognized as a key driver of epileptogenesis and seizure generation, contributing to neuronal hyperexcitability and network instability. However, the potential mechanisms linking MitD to epilepsy remain incompletely understood. This study aimed to identify MitD-related biomarkers in epilepsy and investigate their associations with alterations in the immune cell infiltration landscape during epileptogenesis. On the basis of the GSE47752 dataset, differential expression analysis was performed to identify differentially expressed genes (DEGs) between the control group and epilepsy groups in the early phase after status epilepticus (SE). The intersection of DEGs across time points yielded core DEGs, which were further intersected with MitD-related genes (MDRGs) to obtain MitD-related differentially expressed genes (MDR-DEGs). Multiple machine learning algorithms (LASSO, Boruta, XGBoost, and SVM-RFE) were applied to identify robust candidate biomarkers through consensus feature selection strategies, prioritizing genes with high stability across different algorithms. Importantly, immune infiltration was analyzed via the single-sample gene set enrichment analysis (ssGSEA) algorithm to characterize the immunological microenvironment in epilepsy. Finally, the expression of candidate biomarkers was validated via RT-qPCR in hippocampal tissues from a lithium-pilocarpine (Li-Pilo) rat model. Machine learning consensus pinpointed three candidate biomarkers: Idi1, Nubpl, and Tspo. Single-gene gene set enrichment analysis (GSEA) revealed that Nubpl and Tspo were significantly enriched in the complement and coagulation cascades pathway. Immune infiltration analysis revealed a substantial increase in the abundance of myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs). The expression of Nubpl and Tspo was strongly positively correlated with that of most of these differentially infiltrated immune cell subsets. RT-qPCR confirmed that Nubpl and Tspo mRNA levels were significantly elevated in the early phase post-SE compared with those in controls, whereas the change in Idi1 expression was not statistically significant. Nubpl and Tspo were identified as key candidate biomarkers associated with MitD in epilepsy. The candidate biomarkers may contribute to epileptogenesis not only through direct mitochondrial pathways but also through crosstalk between complement and coagulation cascades and immune cell dynamics. These findings offer novel insights into the integrative molecular and immunological mechanisms linking MitD to epilepsy, highlighting potential therapeutic targets.
- 1 January 2026
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 627
Identification of Mitochondrial Dysfunction-Related Candidate Biomarkers and Analysis of the Immune Cell Infiltration in Epilepsy
Epilepsy is a severe neurological disorder with complex pathogenesis. Mitochondrial dysfunction (MitD) is increasingly recognized as a key driver of epileptogenesis and seizure generation, contributing to neuronal hyperexcitability and network instability. However, the potential mechanisms linking MitD to epilepsy remain incompletely understood. This study aimed to identify MitD-related biomarkers in epilepsy and investigate their associations with alterations in the immune cell infiltration landscape during epileptogenesis. On the basis of the GSE47752 dataset, differential expression analysis was performed to identify differentially expressed genes (DEGs) between the control group and epilepsy groups in the early phase after status epilepticus (SE). The intersection of DEGs across time points yielded core DEGs, which were further intersected with MitD-related genes (MDRGs) to obtain MitD-related differentially expressed genes (MDR-DEGs). Multiple machine learning algorithms (LASSO, Boruta, XGBoost, and SVM-RFE) were applied to identify robust candidate biomarkers through consensus feature selection strategies, prioritizing genes with high stability across different algorithms. Importantly, immune infiltration was analyzed via the single-sample gene set enrichment analysis (ssGSEA) algorithm to characterize the immunological microenvironment in epilepsy. Finally, the expression of candidate biomarkers was validated via RT-qPCR in hippocampal tissues from a lithium-pilocarpine (Li-Pilo) rat model. Machine learning consensus pinpointed three candidate biomarkers: Idi1, Nubpl, and Tspo. Single-gene gene set enrichment analysis (GSEA) revealed that Nubpl and Tspo were significantly enriched in the complement and coagulation cascades pathway. Immune infiltration analysis revealed a substantial increase in the abundance of myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs). The expression of Nubpl and Tspo was strongly positively correlated with that of most of these differentially infiltrated immune cell subsets. RT-qPCR confirmed that Nubpl and Tspo mRNA levels were significantly elevated in the early phase post-SE compared with those in controls, whereas the change in Idi1 expression was not statistically significant. Nubpl and Tspo were identified as key candidate biomarkers associated with MitD in epilepsy. The candidate biomarkers may contribute to epileptogenesis not only through direct mitochondrial pathways but also through crosstalk between complement and coagulation cascades and immune cell dynamics. These findings offer novel insights into the integrative molecular and immunological mechanisms linking MitD to epilepsy, highlighting potential therapeutic targets.
- 13 May 2025
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (5) , 1-14
ROS-responsive dextran-benzeneboronic acid pinacol ester micelles encapsulating edaravone for the treatment and mechanism of cerebral ischemia-reperfusion injury
Reperfusion, while essential for restoring blood supply, paradoxically exacerbates neuronal damage through cerebral ischemia-reperfusion injury (CIRI). This study aimed to develop a reactive oxygen species (ROS)-responsive drug delivery system (DDS) loaded with edaravone (EDA) to enhance targeted therapy for CIRI. The stimuli-responsive DDS was synthesized using dextran (DEX) as the biocompatible carrier and benzeneboronic acid pinacol ester (BAPE) as the ROS-sensitive moiety. The physicochemical characteristics of the DEX-BAPE/EDA (DB/EDA) micelles were systematically evaluated. In vitro studies assessed the anti-inflammatory, antioxidant, and anti-apoptotic effects of DB/EDA. Moreover, the neuroprotective efficacy of DB/EDA in vivo was analyzed via behavioral tests, infarct volume measurement, ELISA assays of inflammatory cytokines and OS markers, and Western blot analysis of Nrf2-related pathways. Pharmacokinetics and biosafety were analyzed through plasma profiling and H&E staining. DB/EDA exhibited high stability, efficient drug encapsulation, and ROS-responsive drug release. Cellular uptake studies confirmed enhanced internalization of DB/EDA micelles in BV2 cells. In the oxygen-glucose deprivation/reoxygenation (OGD/R) model, DB/EDA significantly suppressed TNF-α, IL-1β, IL-6, and MDA, restored SOD levels, and attenuated apoptosis. In the middle cerebral artery occlusion/reperfusion (MCAO/R) mice, DB/EDA administration effectively improves cognition and mitigates neuronal damage. Mechanistically, DB/EDA activated the Nrf2/HO-1 pathway, amplifying antioxidant and anti-inflammatory responses. Pharmacokinetic analysis revealed prolonged circulation and increased brain accumulation, and histopathological analysis demonstrated the safety profile of DB/EDA. The ROS-responsive DB/EDA nano-micelles provided targeted EDA delivery to ischemic brain regions, alleviating CIRI via Nrf2 activation, suggesting that DB/EDA is a promising strategy for CIRI treatment. Graphical abstract
- 13 May 2025
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (5) , 1-14
ROS-responsive dextran-benzeneboronic acid pinacol ester micelles encapsulating edaravone for the treatment and mechanism of cerebral ischemia-reperfusion injury
Reperfusion, while essential for restoring blood supply, paradoxically exacerbates neuronal damage through cerebral ischemia-reperfusion injury (CIRI). This study aimed to develop a reactive oxygen species (ROS)-responsive drug delivery system (DDS) loaded with edaravone (EDA) to enhance targeted therapy for CIRI. The stimuli-responsive DDS was synthesized using dextran (DEX) as the biocompatible carrier and benzeneboronic acid pinacol ester (BAPE) as the ROS-sensitive moiety. The physicochemical characteristics of the DEX-BAPE/EDA (DB/EDA) micelles were systematically evaluated. In vitro studies assessed the anti-inflammatory, antioxidant, and anti-apoptotic effects of DB/EDA. Moreover, the neuroprotective efficacy of DB/EDA in vivo was analyzed via behavioral tests, infarct volume measurement, ELISA assays of inflammatory cytokines and OS markers, and Western blot analysis of Nrf2-related pathways. Pharmacokinetics and biosafety were analyzed through plasma profiling and H&E staining. DB/EDA exhibited high stability, efficient drug encapsulation, and ROS-responsive drug release. Cellular uptake studies confirmed enhanced internalization of DB/EDA micelles in BV2 cells. In the oxygen-glucose deprivation/reoxygenation (OGD/R) model, DB/EDA significantly suppressed TNF-α, IL-1β, IL-6, and MDA, restored SOD levels, and attenuated apoptosis. In the middle cerebral artery occlusion/reperfusion (MCAO/R) mice, DB/EDA administration effectively improves cognition and mitigates neuronal damage. Mechanistically, DB/EDA activated the Nrf2/HO-1 pathway, amplifying antioxidant and anti-inflammatory responses. Pharmacokinetic analysis revealed prolonged circulation and increased brain accumulation, and histopathological analysis demonstrated the safety profile of DB/EDA. The ROS-responsive DB/EDA nano-micelles provided targeted EDA delivery to ischemic brain regions, alleviating CIRI via Nrf2 activation, suggesting that DB/EDA is a promising strategy for CIRI treatment. Graphical abstract
- Open Access
- 5 March 2025
- Published by China Science Publishing & Media Ltd. in Acta Biochimica et Biophysica Sinica
- Vol. 57 (6) , 955-967
Gastrodin inhibits reactive astrocyte-mediated inflammation in hypoxic-ischemic brain damage through S100B/RAGE-Smad3 signaling
Activated astrocytes and their associated inflammatory responses play critical roles in the pathogenesis of hypoxic-ischemic brain damage (HIBD). Gastrodin (GAS), an anti-inflammatory herbal agent, is known to suppress microglial activation. Here, we investigate whether it exerts a similar effect on activated astrocytes and whether it may act through S100B/RAGE-Smad3 signaling. The expression changes of S100B/RAGE-Smad3 signaling pathway related proteins, inflammatory factors and A1/A2 astrocyte markers were detected by ELISA, western blotting, immunofluorescence and immunohistochemistry. The results show that GAS decreases the expression of sRAGE in the brain tissue and S100B in the serum and brain tissue of HIBD mice. However, it promotes the expression of sRAGE in the serum of HIBD mice. Moreover, GAS inhibits the expressions of RAGE, C3, TNF-α, and p-Smad3 and promotes the expressions of S100A10 and BDNF in HIBD model mice, as well as in oxygen glucose deprivation (OGD)-treated TNC-1 astrocytes. The results of RAGE and p-Smad3 immunofluorescence reveals the same trend. Interestingly, FPS-ZM1 (a specific inhibitor of RAGE) inhibits the expression of p-Smad3, TNF-α, C3, and S100A10 (an A2 astrocyte marker), but promotes that of BDNF compared with those in the OGD group. The combination of GAS and FPS-ZM1 further decreases the expression of C3 (an A1 astrocyte marker). These results indicate that GAS can inhibit the activation of Smad3 through S100B/RAGE signaling and regulate the expression of A1/A2-type astrocytes.
- 5 March 2025
- Published by China Science Publishing & Media Ltd. in Acta Biochimica et Biophysica Sinica
- Vol. 57 (6) , 955-967
Open AccessGastrodin inhibits reactive astrocyte-mediated inflammation in hypoxic-ischemic brain damage through S100B/RAGE-Smad3 signaling
Activated astrocytes and their associated inflammatory responses play critical roles in the pathogenesis of hypoxic-ischemic brain damage (HIBD). Gastrodin (GAS), an anti-inflammatory herbal agent, is known to suppress microglial activation. Here, we investigate whether it exerts a similar effect on activated astrocytes and whether it may act through S100B/RAGE-Smad3 signaling. The expression changes of S100B/RAGE-Smad3 signaling pathway related proteins, inflammatory factors and A1/A2 astrocyte markers were detected by ELISA, western blotting, immunofluorescence and immunohistochemistry. The results show that GAS decreases the expression of sRAGE in the brain tissue and S100B in the serum and brain tissue of HIBD mice. However, it promotes the expression of sRAGE in the serum of HIBD mice. Moreover, GAS inhibits the expressions of RAGE, C3, TNF-α, and p-Smad3 and promotes the expressions of S100A10 and BDNF in HIBD model mice, as well as in oxygen glucose deprivation (OGD)-treated TNC-1 astrocytes. The results of RAGE and p-Smad3 immunofluorescence reveals the same trend. Interestingly, FPS-ZM1 (a specific inhibitor of RAGE) inhibits the expression of p-Smad3, TNF-α, C3, and S100A10 (an A2 astrocyte marker), but promotes that of BDNF compared with those in the OGD group. The combination of GAS and FPS-ZM1 further decreases the expression of C3 (an A1 astrocyte marker). These results indicate that GAS can inhibit the activation of Smad3 through S100B/RAGE signaling and regulate the expression of A1/A2-type astrocytes.
- Open Access
- 6 April 2023
- Published by Wiley in Mediators of Inflammation
- Vol. 2023, 1-17
MALAT1 Mediates α-Synuclein Expression through miR-23b-3p to Induce Autophagic Impairment and the Inflammatory Response in Microglia to Promote Apoptosis in Dopaminergic Neuronal Cells
Background. Parkinsons disease (PD) is a very common neurodegenerative disease that adversely affects the physical and mental health of many patients, but there is currently no effective treatment. Objective. To this end, this study focused on investigating the potential mechanisms leading to dopaminergic neuronal apoptosis in PD. Methods. Rotenone induces damage in dopaminergic neuronal MN9D cells. Apoptosis was detected by flow cytometry, and the expression of apoptosis-related proteins was detected by western blot. RT-qPCR was used to detect the expression of MALAT1 and miR-23b-3p. The expression of α-synuclein was detected by ELISA. A dual luciferase gene reporter assay was used to determine the targeted regulatory relationship between MALAT1 and miR-23b-3p and miR-23b-3p and α-synuclein. MN9D supernatant was cocultured with BV-2 cells, or BV-2 cells were treated with exogenous α-synuclein and then treated with an autophagy inhibitor (3-MA) and autophagy activator (RAPA). The expression of α-synuclein in BV-2 cells was detected by immunofluorescence. The expression of MIP-1α, a marker of microglial activation, was detected by ELISA. The nuclear translocation of NF-κB p65 was detected by immunofluorescence. The expression of proinflammatory cytokines was detected by ELISA. Western blotting was used to detect the expression of autophagy-related proteins. Apoptosis of MN9D cells was detected after coculture of BV-2 supernatant with MN9D. Results. The expression of MALAT1 and α-synuclein was upregulated, while the expression of miR-23b-3p was downregulated in damaged MN9D cells, resulting in cell apoptosis. MALAT1 can negatively regulate the expression of miR-23b-3p, while miR-23b-3p negatively regulates the expression of α-synuclein. α-synuclein can enter BV-2 cells through cell phagocytosis. Coculture of BV-2 cells with α-synuclein or with MN9D supernatant overexpressing MALAT1 resulted in a decrease in the autophagy level of BV-2 cells and an inflammatory reaction. However, miR-23b-3p mimics and knockdown of α-synuclein reversed the effect of MALAT1 on autophagy and the inflammatory response of BV-2 cells. In addition, after coculture of BV-2 cells with α-synuclein, the level of autophagy further decreased when 3-MA was added, while the opposite result occurred when RAPA was added. After coculture of α-synuclein-treated BV-2 cell supernatant with MN9D cells, autophagy-impaired BV-2 promoted the apoptosis of MN9D cells, and 3-MA aggravated the autophagy disorder of BV-2 and further promoted the apoptosis of MN9D cells, while RAPA reversed the autophagy disorder of BV-2 and alleviated the apoptosis of MN9D cells. Conclusion. MALAT1 can promote α-synuclein expression by regulating miR-23b-3p, thereby inducing microglial autophagy disorder and an inflammatory response leading to apoptosis of dopaminergic neurons. This newly discovered molecular mechanism may provide a potential target for the treatment of PD.
- 6 April 2023
- Published by Wiley in Mediators of Inflammation
- Vol. 2023, 1-17
Open AccessMALAT1 Mediates α-Synuclein Expression through miR-23b-3p to Induce Autophagic Impairment and the Inflammatory Response in Microglia to Promote Apoptosis in Dopaminergic Neuronal Cells
Background. Parkinsons disease (PD) is a very common neurodegenerative disease that adversely affects the physical and mental health of many patients, but there is currently no effective treatment. Objective. To this end, this study focused on investigating the potential mechanisms leading to dopaminergic neuronal apoptosis in PD. Methods. Rotenone induces damage in dopaminergic neuronal MN9D cells. Apoptosis was detected by flow cytometry, and the expression of apoptosis-related proteins was detected by western blot. RT-qPCR was used to detect the expression of MALAT1 and miR-23b-3p. The expression of α-synuclein was detected by ELISA. A dual luciferase gene reporter assay was used to determine the targeted regulatory relationship between MALAT1 and miR-23b-3p and miR-23b-3p and α-synuclein. MN9D supernatant was cocultured with BV-2 cells, or BV-2 cells were treated with exogenous α-synuclein and then treated with an autophagy inhibitor (3-MA) and autophagy activator (RAPA). The expression of α-synuclein in BV-2 cells was detected by immunofluorescence. The expression of MIP-1α, a marker of microglial activation, was detected by ELISA. The nuclear translocation of NF-κB p65 was detected by immunofluorescence. The expression of proinflammatory cytokines was detected by ELISA. Western blotting was used to detect the expression of autophagy-related proteins. Apoptosis of MN9D cells was detected after coculture of BV-2 supernatant with MN9D. Results. The expression of MALAT1 and α-synuclein was upregulated, while the expression of miR-23b-3p was downregulated in damaged MN9D cells, resulting in cell apoptosis. MALAT1 can negatively regulate the expression of miR-23b-3p, while miR-23b-3p negatively regulates the expression of α-synuclein. α-synuclein can enter BV-2 cells through cell phagocytosis. Coculture of BV-2 cells with α-synuclein or with MN9D supernatant overexpressing MALAT1 resulted in a decrease in the autophagy level of BV-2 cells and an inflammatory reaction. However, miR-23b-3p mimics and knockdown of α-synuclein reversed the effect of MALAT1 on autophagy and the inflammatory response of BV-2 cells. In addition, after coculture of BV-2 cells with α-synuclein, the level of autophagy further decreased when 3-MA was added, while the opposite result occurred when RAPA was added. After coculture of α-synuclein-treated BV-2 cell supernatant with MN9D cells, autophagy-impaired BV-2 promoted the apoptosis of MN9D cells, and 3-MA aggravated the autophagy disorder of BV-2 and further promoted the apoptosis of MN9D cells, while RAPA reversed the autophagy disorder of BV-2 and alleviated the apoptosis of MN9D cells. Conclusion. MALAT1 can promote α-synuclein expression by regulating miR-23b-3p, thereby inducing microglial autophagy disorder and an inflammatory response leading to apoptosis of dopaminergic neurons. This newly discovered molecular mechanism may provide a potential target for the treatment of PD.
- Open Access
- 7 December 2022
- Published by Springer Nature in Acta Epileptologica
- Vol. 4 (1) , 1-6
Development of localized interictal epileptiform discharges following vagus nerve stimulation for lennox-gastaut syndrome: a case report
Background: Lennox-gastaut syndrome (LGS) is an epileptic encephalopathy often associated with behavioral and psychiatric disorders. Vagus nerve stimulation (VNS) has been approved effective for LGS treatment. Surgical resection is also an option for LGS patients with focal pathology, offering a high probability of seizure control. However, it is challenging to accurately localize the seizure focus. Case presentation: The case presented here is a 19-year-old male with a 16-year history of epilepsy with comorbid severe cognitive and psychiatric disorders. He was diagnosed with LGS due to generalized slow spike-wave discharges and multiple seizure types. He was treated with VNS in 2017 at the age of 15. After that, the frequency of the short tonic seizures decreased from 4–5 times per day to 2–5 times per year, and the generalized tonic–clonic seizure pattern did not recur, which had a frequency of 2–4 times per month before the surgery. In 2019, the generalized abnormal interictal epileptiform discharges changed to be localized in the right frontal–temporal lobe at the age of 17 years (2019). Conclusions: This case report suggested that the generalized epileptiform discharges evolve into localized discharges after VNS treatment, which may help reveal the primary seizure focus for resection surgery in patients with LGS.
- 7 December 2022
- Published by Springer Nature in Acta Epileptologica
- Vol. 4 (1) , 1-6
Open AccessDevelopment of localized interictal epileptiform discharges following vagus nerve stimulation for lennox-gastaut syndrome: a case report
Background: Lennox-gastaut syndrome (LGS) is an epileptic encephalopathy often associated with behavioral and psychiatric disorders. Vagus nerve stimulation (VNS) has been approved effective for LGS treatment. Surgical resection is also an option for LGS patients with focal pathology, offering a high probability of seizure control. However, it is challenging to accurately localize the seizure focus. Case presentation: The case presented here is a 19-year-old male with a 16-year history of epilepsy with comorbid severe cognitive and psychiatric disorders. He was diagnosed with LGS due to generalized slow spike-wave discharges and multiple seizure types. He was treated with VNS in 2017 at the age of 15. After that, the frequency of the short tonic seizures decreased from 4–5 times per day to 2–5 times per year, and the generalized tonic–clonic seizure pattern did not recur, which had a frequency of 2–4 times per month before the surgery. In 2019, the generalized abnormal interictal epileptiform discharges changed to be localized in the right frontal–temporal lobe at the age of 17 years (2019). Conclusions: This case report suggested that the generalized epileptiform discharges evolve into localized discharges after VNS treatment, which may help reveal the primary seizure focus for resection surgery in patients with LGS.
- 21 January 2022
- Published by Elsevier in Brain Research
- Vol. 1780, 147800
Chronic vagus nerve stimulation (VNS) altered IL-6, IL-1β, CXCL-1 and IL-13 levels in the hippocampus of rats with LiCl-pilocarpine-induced epilepsy
- 21 January 2022
- Published by Elsevier in Brain Research
- Vol. 1780, 147800
Chronic vagus nerve stimulation (VNS) altered IL-6, IL-1β, CXCL-1 and IL-13 levels in the hippocampus of rats with LiCl-pilocarpine-induced epilepsy
- 20 July 2021
- Published by Elsevier in Journal of Neuroscience Methods
- Vol. 362, 109291
A pilot behavioural and neuroimaging investigation on photothrombotic stroke models in rhesus monkeys
- 20 July 2021
- Published by Elsevier in Journal of Neuroscience Methods
- Vol. 362, 109291
A pilot behavioural and neuroimaging investigation on photothrombotic stroke models in rhesus monkeys
- Open Access
- 1 May 2021
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 9 (10) , 844
Electroacupuncture promotes the recovery of rats with spinal cord injury by suppressing the Notch signaling pathway via the H19/ EZH2 axis
Background: Spinal cord injury (SCI) is a life-changing event with an extremely poor prognosis. In our preliminary studies, electroacupuncture (EA) was found to promote the repair of SCI, which was closely related to the Notch signaling pathway. Therefore, in the present study, we hypothesized that EA protects against SCI by inhibiting the Notch signaling pathway and sought to investigate the underlying molecular mechanisms. Methods: Rat and cell models of SCI were established. The expression of long non-coding RNA H19 was measured by real-time quantitative polymerase chain reaction. The expression levels of EZH2, Notch1, Notch3, Notch4, Hes1, and PS1 protein were measured by western blot. Cell apoptosis and viability were analyzed using flow cytometry and Cell Counting Kit-8 assays, respectively. The expressions of glial fibrillary acidic protein (GFAP) and nestin were detected by immunofluorescence staining. Results: The expressions of H19, EZH2, and GFAP were significantly increased after SCI but were inhibited by EA; in contrast, nestin expression was significantly decreased by SCI but was restored by EA. Moreover, oxygen-glucose deprivation (OGD) treatment elevated the expression of H19, EZH2, and Notch-related factors as well as apoptosis in PC-12 cells, while suppressing cell viability. Suppressing H19 alleviated the effects of OGD on cell viability and apoptosis, and inhibited the expression of EZH2 and Notch-related factors expression; these effects were reversed by EZH2 overexpression. Finally, EA promoted the recovery of SCI rats and neural stem cell (NSC) proliferation by inhibiting the Notch signaling pathway, which was reversed by H19 overexpression. Conclusions: Our results demonstrated that EA promotes the recovery of SCI rats and increases the proliferation and differentiation of NSCs by suppressing the Notch signaling pathway via modulating the H19/EZH2 axis.
- 1 May 2021
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 9 (10) , 844
Open AccessElectroacupuncture promotes the recovery of rats with spinal cord injury by suppressing the Notch signaling pathway via the H19/ EZH2 axis
Background: Spinal cord injury (SCI) is a life-changing event with an extremely poor prognosis. In our preliminary studies, electroacupuncture (EA) was found to promote the repair of SCI, which was closely related to the Notch signaling pathway. Therefore, in the present study, we hypothesized that EA protects against SCI by inhibiting the Notch signaling pathway and sought to investigate the underlying molecular mechanisms. Methods: Rat and cell models of SCI were established. The expression of long non-coding RNA H19 was measured by real-time quantitative polymerase chain reaction. The expression levels of EZH2, Notch1, Notch3, Notch4, Hes1, and PS1 protein were measured by western blot. Cell apoptosis and viability were analyzed using flow cytometry and Cell Counting Kit-8 assays, respectively. The expressions of glial fibrillary acidic protein (GFAP) and nestin were detected by immunofluorescence staining. Results: The expressions of H19, EZH2, and GFAP were significantly increased after SCI but were inhibited by EA; in contrast, nestin expression was significantly decreased by SCI but was restored by EA. Moreover, oxygen-glucose deprivation (OGD) treatment elevated the expression of H19, EZH2, and Notch-related factors as well as apoptosis in PC-12 cells, while suppressing cell viability. Suppressing H19 alleviated the effects of OGD on cell viability and apoptosis, and inhibited the expression of EZH2 and Notch-related factors expression; these effects were reversed by EZH2 overexpression. Finally, EA promoted the recovery of SCI rats and neural stem cell (NSC) proliferation by inhibiting the Notch signaling pathway, which was reversed by H19 overexpression. Conclusions: Our results demonstrated that EA promotes the recovery of SCI rats and increases the proliferation and differentiation of NSCs by suppressing the Notch signaling pathway via modulating the H19/EZH2 axis.